Market Place
Sourcing Support
JW Therapeutics Announces NMPA Approval For Carteyva In Lymphoma Patients
27 Aug 2024 //
PR NEWSWIRE
Relma-Cel Data In Lupus Patients Presented At Eular 2024 Congress
30 May 2024 //
PR NEWSWIRE
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel
10 Apr 2023 //
PR NEWSWIRE
JW Announces Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
29 Mar 2023 //
PR NEWSWIRE
JW Therapeutics Announces Initiation of Study of Carteyva for Large B-Cell Lymphoma
08 Mar 2023 //
PR NEWSWIRE
JW Therapeutics Announces Initiation of Clinical Study of JWATM214
28 Feb 2023 //
PR NEWSWIRE
JW Therapeutics Presents Latest Clinical Data on Carteyva at ASH
12 Dec 2022 //
PRNEWSWIRE
2seventy and JW Therapeutics partner to develop immunotherapies
28 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
2seventy bio and JW Therapeutics Announce Strategic Partnership
27 Oct 2022 //
BUSINESSWIRE
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection
10 Oct 2022 //
PRNEWSWIRE
JW Therapeutics Initiates Study of JWATM204 in Advanced HCC
04 Jul 2022 //
ASIAONE
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully
25 Apr 2022 //
PRNEWSWIRE
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva
20 Apr 2022 //
PRNEWSWIRE
JW Therapeutics Receives BTD for Carteyva in Mantle Cell Lymphoma in China
03 Apr 2022 //
PRNEWSWIRE
JW Therapeutics Announces IND Approval for Trial of Carteyva in BCL
30 Mar 2022 //
PRNEWSWIRE
NMPA Accepts sNDA of JW Therapeutics` Carteyva in r/r Follicular Lymphoma
28 Feb 2022 //
PRNEWSWIRE
JW Therapeutics Presents Primary Clinical Response on Carteyva
15 Dec 2021 //
PRNEWSWIRE
JW Therapeutics Announces Updated 1yFollow-up Result Relmacabtagene Inj
25 Sep 2021 //
ASIAONE
JW Therapeutics Claims Approval of Autoleucel Relmacabtagen Injection in China
08 Sep 2021 //
PRNEWSWIRE
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection
07 Sep 2021 //
PRNEWSWIRE
NMPA Approves JW Therapeutics` Relmacabtagene Autoleucel Injection in China
06 Sep 2021 //
PRNEWSWIRE
Juno, WuXi JV wins China nod for Breyanzi sister CAR-T
03 Sep 2021 //
FIERCEPHARMA
JW`s relma-cel lands second-ever CAR-T approval in China
03 Sep 2021 //
ENDPTS
JW Therapeutics: NMPA Approval Of Relmacabtagene Autoleucel Injection In China
03 Sep 2021 //
PRESS RELEASE
JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH
07 Dec 2020 //
PRNEWSWIRE
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T
04 Nov 2020 //
ENDPTS
Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China`s CAR-T
17 Aug 2020 //
ENDPTS
Juno joint venture seeks IPO haul to bring CAR-Ts to China
17 Aug 2020 //
FIERCEBIOTECH
JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’
20 Jul 2020 //
BUSINESSWIRE
JW Acquires Syracuse Biopharma and License to Eureka
20 Jul 2020 //
BUSINESSWIRE
Acepodia & JW Enter into Option and License Agreement for Off-the-shelf NK
14 Jul 2020 //
GLOBENEWLSWIRE
